cyrilzakka/clinical-trials huggingface dataset:
Corneal Epithelial Autograft for Limbal Dermoid

The purpose of the study is to explore whether femtosecond laser-assisted corneal epithelial autograft is more effective than femtosecond laser-assisted limbal autograft for ocular surface reconstruction after excision of limbal dermoid.


Eligibility Criteria:
Inclusion Criteria:

1. Age between 1 to 30 years old;
2. Patients with limbal dermoid, scheduled for elective surgical excision;
3. Superficial lesion ranging from 5 to 9mm, without encroaching the deep stroma layer, as indicated by anterior segment optical coherence tomography images;
4. Informed consent signed by a parent or legal guardian, or having the capability of understanding and signing the informed consent;
5. Being able to comply with study assessments for the full duration of the study.

Exclusion Criteria:

1. Keratoconus;
2. Ocular and facial active inflammation such as keratitis, trachoma, dacryocystitis, blepharitis, meibomian gland dysfunction, Sjogren's syndrome, cicatricial pemphigoid etc;
3. High myopia with a spherical equivalent of -15.0 D or less;
4. Corneal or ocular surface infection within 30 days prior to study entry;
5. Ocular surface malignancy;
6. Uncontrolled diabetes with most recent Hemoglobin A1c greater than 8.5%;
7. Renal failure with creatinine clearance\< 25ml/min;
8. Alanine aminotransferase \> 40IU/L, or aspartate aminotransferase \> 40IU/L;
9. Platelet levels \< 150,000 or \> 450,000 per microliter;
10. Hemoglobin \< 12.0 g/dL (male) or \< 11.0 g/dL (female);
11. Prothrombin time \> 16s and activated partial thrombin time \> 35s in patients not accepting anticoagulant therapy; An international normalized ratio greater than 3 in patients accepting anticoagulant therapy;
12. Pregnancy (positive test) or lactation;
13. Participation in another simultaneous medical investigation or clinical trial;
14. Severe cicatricial eye disease;
15. Ocular comorbidities that affect the prognosis of transplantation, such as advanced glaucoma or retinal diseases;
16. Severe dry eye disease as determined by Schirmer's test \< 2mm at least in one eye;
17. Any medical or social condition that in the judgement of the investigator would interfere with or serve as a contraindication to adherence to the study protocol or ability to give informed consent;
18. Signs of current infection, including fever and treatment with antibiotics;
19. Active immunological diseases;
20. History of allo-limbal transplantation, penetrating keratoplasty or anti-glaucoma filtering surgeries.
Effect of Skanlab Regarding Knee Arthrosis

The purpose is to find out the effect of Skanlab at knee arthrosis.

The patients diagnosed with knee arthrosis will be treated With Skanlab twice a week for four weeks.

Eligibility Criteria:
Inclusion Criteria:

* knee arthrosis in one or both legs

Exclusion Criteria:

* Pacemaker
* infusion pump
* cancer
* diabetes
* pregnancy
* blood clots
* bacteriological inflammation
* reduced sensitivity in the treatment area.
Effectiveness of the RemedRugby Program

REMEDRUGBY's objective is to strengthen the capacity of users to interact with others in an assertive way and to fight against stigma. It proposes to specifically target the processes of "social cognition".

"Social cognition" brings together the mental mechanisms that allow everyone to decipher the social situations, emotions and intentions of others and interact with others in the different contexts of everyday life.

People with a psychic handicap frequently have difficulties in this area, which has often important consequences for their social and professional integration.

The REMEDRUGBY program proposes to work specifically on these processes in the context of sport (+ role Play and blog) to strengthen the ability to interact with others and to deal with the stigma that can be encountered on a daily basis.


Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of schizophrenia, schizo-affective disorder (DSM-V criteria; APA, 2013).
* French mother tongue.
* psychotropic treatment unchanged during the month prior to inclusion.
* Patients who gave their informed consent to participate in the study.
* affiliated with a social security scheme or beneficiary of such a scheme
* Subject suitable for the practice of sport.

Exclusion Criteria:

* Recent dependence and abuse on cannabis or any other substance (DSM-V criteria), except tobacco.
* Neurological disorders of vascular, infectious or neurodegenerative origin.
* taking of medicinal products with a cerebral or psychic impact (e.g., corticosteroids).
* Inability to practice sport
* Pregnancy planned or in progress
* Simultaneous Participation in any other program of remediation of social cognition, training in social skills, self-esteem.
Characterization of the Cardiac Reinnervation of Patients With Transposition of the Great Arteries Long After Repair With the Arterial Switch Operation. Correlation With Electrocardiographic and Exercise Test Parameters

Cardiac denervation is inherent to the arterial switch (ASO) technique for the repair of transposition of the great arteries (TGA) and the long term reinnervation process has not been studied. We sought to describe the reinnervation status of adult patients long after the ASO, to identify areas of myocardial perfusion/innervation mismatch and to assess the relation of innervation status and exercise capacity.

Cardiac denervation is inherent to the arterial switch (ASO) technique for the repair of transposition of the great arteries (TGA) and the long term reinnervation process has not been studied. We sought to describe the reinnervation status of adult patients long after the ASO, to identify areas of myocardial perfusion/innervation mismatch and to assess the relation of innervation status and exercise capacity.

Eligibility Criteria:
Inclusion Criteria:

* Patients with transposition of the great arteries repaired with the arterial switch.
* Patients aged of more than 18 years-old.

Exclusion Criteria:

* Pregnancy or breast-feeding.
* Denial of informed consent.
Ultrasound Assessment of Isolated Distal Deep Vein Thrombosis

Retrospective assessment of ultrasound and clinical characteristics of patients with IDDVT, development of a pulmonary embolism risk prediction model for thrombus, and provision of appropriate diagnostic and therapeutic recommendations.


Eligibility Criteria:
Inclusion Criteria:

Diagnosis of new-onset IDDVT confirmed by lower limb vascular ultrasound; presence/absence of pulmonary embolism clarified by pulmonary artery CTA; ultrasound and pulmonary artery CTA results spanning no more than 5 days.

Exclusion Criteria:

Anticoagulation therapy in the last month; pregnancy or puerperium; recurrent DVT or PE.
Investigation of Ascending Concentrations of Glycopyrronium Bromide (GPB) in a Topical Formulation in Subjects With Axillary Hyperhidrosis

The aim of the study is to assess the safety, tolerability, pharmacokinetics (PK) and efficacy of escalating concentrations of GPB in subjects with axillary hyperhidrosis.


Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of moderate to severe primary axillary hyperhidrosis whose HDSS score is 2, 3 or 4
* At least 50 mg in males or 25 mg in females of spontaneous resting axillary sweat production in one axilla measured gravimetrically at room temperature/humidity (about 25°C / 20-50%) over a period of 5 minutes.
* Male and female subjects in the age of 18 to 65 years at the time of informed consent and a body mass index (BMI) of 18-32 kg/m2.
* Corrected QT (QTc) ≤450 msec, or QTc \<480 msec in subjects with bundle branch block.
* Able to comply with protocol requirements, including overnight stays, blood sample collections as defined in the protocol subjects.
* Willing and able to provide written informed consent.

Exclusion Criteria:

* Known allergy to any of the components in the investigational product.
* Hypersensitivity against glycopyrrolate
* Secondary hyperhidrosis, for example, hyperhidrosis that is secondary to other underlying diseases including hyperthyroidism, lymphoma and malaria, climacteric hyperhidrosis.
* Previous surgical treatment of hyperhidrosis including sympathectomy, surgical debulking of the sweat glands, subcutaneous tissue curettage and ultrasonic surgery.
* Botulinum toxin treatment in the prior 9 months.
* Present or history of neuromuscular disease.
* Angle closure glaucoma or its precipitation (narrow angle).
* Mycotic, other skin infections and other dermal disorder including infection at anticipated application sites in either axilla.
* Significant cardiac arrhythmia such as tachycardiac atrial fibrillation and very frequent extrasystoles.
* Subject with diabetes mellitus.
* Subjects with ileus, gastrointestinal stenosis, pronounced chronic inflammatory bowel disease, toxic megacolon.
* Subjects with epilepsy.
* Use of antiperspirants containing aluminium chloride and deodorants, any oral herbal medicine treatments or any other topical treatments for hyperhidrosis within 7 days prior to study treatment.
Split-face Tolerability Comparison Between Adapalene-Benzoyl Peroxide Gel Versus Tretinoin Gel

To compare the tolerability of Epiduo® (adapalene and benzoyl peroxide) Gel 0.1%/2.5% to Retin-A Micro® (tretinoin gel) microsphere when used by subjects with acne vulgaris for 3 weeks in terms of local tolerability parameters (erythema, dryness, scaling, stinging/burning) and preference.

Adult subjects with acne vulgaris will receive tretinoin gel 0.1% on one side of the face and adapalene 0.1% / benzoyl peroxide 2.5% gel on the other side of the face once daily for a period 3 weeks (22 days). Tolerability assessments (erythema, dryness, scaling, stinging/burning)on both sides of the face will be taken on each visit, on each weekday from from baseline to day 22. The investigator and subjects will respond to user preference questions on days 5, 12, 19, and 22.

Eligibility Criteria:
Inclusion Criteria:

* Male and female subjects of any race
* Subjects 18 years or older
* Subjects with acne vulgaris

Exclusion Criteria:

* Subjects with an allergy to a component of the study drugs (refer to the package inserts for Epiduo Gel and Retin-A Micro 0.1%)
* Subjects with a washout period for topical treatment (less than 1 week for corticosteroids or 4 weeks for retinoids)
* Subjects with a washout period for systemic treatment (less than 1 week for medications that may have increased photosensitivity or 4 weeks for corticosteroids or 24 weeks for oral retinoids)
* Subjects with a sunburn, eczema, atopic dermatitis, perioral dermatitis, rosacea, or other topical conditions on the treatment area
* Subjects with planned unprotected and intense UV exposure during the study (mountain sports, UV radiation, sunbathing, etc)
Dry Needling Dosage in the Treatment of Myofascial Neck Pain

The purpose of this study are (1) to determine the effectiveness of different dry needling dosages in the treatment of myofascial trigger points in the upper trapezius muscle in patients with myofascial neck pain, (2) to assess postneedling soreness and tenderness and (3) evaluate the influence of psychological factors on the perception of postneedling soreness.


Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of an active myofascial trigger point. Neck pain: Superior to 3 cm in VAS

Exclusion Criteria:

* Neck area: Fracture, radiculopathy, previous surgery, previous needling treatment in the last 6 months, previous analgesic medication (24 hours), psychiatric disease
Comparison of Dialysis Therapies on Cognitive Function

This study will evaluate the effects of more frequent dialysis on cognitive function including the assessment of sleep apnea and restless legs. Our hypothesis is that more frequent dialysis improves cognitive function and may have important implications on clinical care of ESRD patients and help to emphasize the need for treatments that will allow patients to live "with dialysis" rather than live "for dialysis".


Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of ESRD
* Age 18 years or greater
* Ability to understand and a willingness to sign an informed consent statement and a Health Insurance Portability and Accountability Act of 1996 (HIPPA) authorization statement.
* Expected survival of at least one year.

Exclusion Criteria:

* Documented non-compliance, defined as missing more than 10% of prescribed treatments during the month prior to the start of the study.
Mindfulness to Mitigate the Effect of Anxiety-depression-fear in Chronic Obstructive Pulmonary Disease (COPD)

People with COPD have a greater risk for symptoms of depression, anxiety, and fear of breathlessness. Those emotions are independently associated with lower physical activity, poorer quality of life, and higher hospitalization and exacerbations; all independent predictors of survival and costs. There is a lack of treatment options to be routinely used in primary clinics for patients with COPD. Systematic reviews suggest that interventions that promote an accepting mode of response, such as mindfulness, might be more appropriate and effective for managing psychological distress in COPD patients, especially breathing-related anxiety.

Hypothesis: A home-based 8-week Mindfulness-Based Stress Reduction (MBSR) for COPD targeted to individuals with symptoms of depression, anxiety, or fear of breathlessness delivered by a mindfulness coach using a combination of in-person sessions and remote video call sessions will be effective in improving emotional and overall quality of life, and measured physical activity.


Eligibility Criteria:
Inclusion criteria:

* Lung disease diagnosis
* Demonstrated competence in proposed technology
* Current or past smoking status
* Patient Health Questionnaire-2 (PHQ-2) or Generalized Anxiety Disorder scale (GAD-2) score \>2 points or answering yes to a validated question of fear of being breathless ("Do you experience fear, or panic when you have difficulty getting your breath a good bit of the time?")

Exclusion criteria:

* High likelihood of non-compliance or low confidence using the technology
* Patients currently in pulmonary rehabilitation
* Inability to walk
* Prescribed antidepressant or antianxiety medication within last month
* Documented substance abuse
* Cognitive impairment as defined by the Mini-Mental test score \< 24.
Neck Movement Implicate the Tracheal Tube-tip Displacement in Pediatric Surgery

This study evaluates the effect of head and neck movement in children on endotracheal tube (ETT) tip displacement undergoing head-and-neck surgeries. The tube-tip displacement will be measured using flexible fiberoptic bronchoscope.

In clinical application, especially in head-and-neck surgeries, the operators often change the position of children's head-neck for easy operating. Flexing the head resulted in the ETT moving towards the carina, and extension resulted in the tube being displaced in the opposite direction. Head and neck movement change the length of trachea as well: extending the head resulted in the extension of trachea, while flexing resulted in the opposite. Serious complications following from head and neck movement, such as accidental extubation and endobronchial intubation, threat children's life.

In pediatric anesthesia, insertion depth (cm) of orotracheal intubation equals to age/2+12, according to classic intubation formulae. The ETT will be put in the depth calculated by the classic formulae under general anesthesia. The distance of ETT-tip displacement and the length change of trachea will be measured as the head and neck placed as follows: fully extended, neutral position, or fully flexed. These three head and neck positions imitate the head-neck movement during those head-and-neck surgeries.

Eligibility Criteria:
Inclusion Criteria:

* subject has elective head-and-neck surgery schedule
* subject will have orotracheal intubation under general anesthesia

Exclusion Criteria:

* subject has malformations of the trachea or bronchus on chest X-ray
* subject has spinal deformity
* subject has difficulties in neck flexion or extension
* subject has neck pain
Efficacy and Safety of Pulsatile Gonadotropin Releasing Hormone Pump Treatment in Patients With Idiopathic Hypogonadotropic Hypogonadism

Idiopathic hypogonadotropic hypogonadism (IHH) is the most common disorders of sex development (DSD).Therapy for IHH includes hormone replacement therapy, gonadotropin therapy and pulsed infusion of gonadotropin releasing hormone (GnRH).In the present study, we compared the different efficacy and safety of pulsatile GnRH pump therapy with combination gonadotropin therapy on fertility and sexual development in male patients with IHH.

Idiopathic hypogonadotropic hypogonadism (IHH) is the most common disorders of sex development (DSD).Therapy for IHH includes hormone replacement therapy, gonadotropin therapy and pulsed infusion of gonadotropin releasing hormone (GnRH).In the present study, we compared the different efficacy and safety of pulsatile GnRH pump therapy with combination gonadotropin therapy on fertility and sexual development in male patients with IHH.

The primary endpoint was the achievement of pregnancy in female partner. Secondary endpoints were time to actual attainment of various sperm thresholds: sperm concentration\>0\*10\^6/ml , \>1.0 \*10\^6/ml and \>15 \*10\^6/ml, respectively.

The clinical and laboratory characteristics including testicular and prostatic volume, Tanner stage for pubic hair and genital, serum hormone levels \[especially serum testosterone,luteinizing hormone (LH) , and Follicle-Stimulating Hormone (FSH) levels\], sperm concentration per ejaculate, and adverse events at baseline and at the end of treatment were also evaluated.

Eligibility Criteria:
Inclusion Criteria:

1. Age greater than 16 yr
2. Diagnosed as idiopathic hypogonadotropic hypogonadism with clinical signs or symptoms of hypogonadism
3. Hypogonadal serum testosterone levels (\<166ng/dl) in the presence of low or normal gonadotropins
4. Normal levels of other anterior pituitary hormones
5. Normal MRI scans of the hypothalamo-pituitary region
6. Had discontinued any prior treatment (testosterone or gonadotropin therapy) for at least three months before enrollment

Exclusion Criteria:

1. With any significant medical condition (including malignant disease), laboratory abnormality, or psychiatric disorders that will prevent the subject from participating in the study
2. Congenital hypopituitarism
3. Any medical or surgical conditions possibly affecting the experiment result
4. Any clinically significant allergic diseases or allergic to the study drugs
5. Recently drug or alcohol abuse(\>35unit/week,1unit=8 g alcohol@1 standard drink@250ml beer@140ml wine@25ml strong alcohol drink like whiskey.)
An Observational Study of the Use of Chloral Hydrate for Ophthalmic Procedures in Children

The study involves a prospective evaluation of chloral hydrate sedation for the measurement of intraocular pressure in children ages one month to five years of age.

This study will be a prospective, non-randomized trial of children 1 month to 5 years of age who are determined to require a sedation procedure at the King Khaled Eye Specialist Hospital (KKESH). There will be two parts to the consent process. Oral consent will be administered to subjects who are not undergoing eye pressure evaluation. These children have chloral hydrate sedation for imaging or other eye evaluations. For these children, we will prospectively monitor the success rate of chloral hydrate sedation such that a complete ophthalmic or imaging evaluation could be performed and will determine the proportion of adverse events that occur due to sedation including vomiting, respiratory distress or depression, alterations in vital signs beyond reference ranges for normal sleeping children, hypoxia with oxygen saturation \<90%, and unplanned hospital admission. No testing will be performed for study purposes on these individuals.

For children undergoing sedation who will have intraocular pressure measurements for clinical care purposes, we will perform additional eye pressure measurements as part of the research protocol. Written consent will be obtained to allow us to additionally measure their intraocular pressure as specified below.

After recruitment and completion of informed consent procedures by parents, subjects' medical and ocular history will be reviewed by a study ophthalmologist and one of two pediatricians overseeing sedation procedures. Patients unable to undergo intraocular pressure measurement due to infection or ocular surface disease and those in whom chloral hydrate sedation is medically contraindicated will be excluded. Age, gender, diagnosis, current medications and surgical history will be recorded from the clinical chart for all subjects.

Eligibility Criteria:
Inclusion Criteria:

* ages 1 month to five years
* require sedation for ophthalmic care

Exclusion Criteria:

* weight \<3 kg or \>20 kg
* infection/ocular surface disease
* medical contraindication of chloral hydrate
* green or gray nasal discharge
* fever, productive cough, chest retractions, or other signs of respiratory infection
* oxygen saturation \< 90%
* active infectious disease such as rubella or varicella
* rectal or tympanic temperature \> 37.7 degrees, or oral or temporal artery temperature \> 37.2 degrees
* history of current ongoing vomiting and diarrhea
* anemia (Hgb \< 9.0mg),
* history of seizure in past 6 weeks
Nitrous Oxide for PTSD

Post-traumatic stress disorder (PTSD) seriously disrupts the lives of many Veterans. Current first-line treatments, serotonin reuptake inhibitors or prolonged exposure therapy, take weeks to months to bring meaningful improvement, leaving Veterans experiencing prolonged suffering. A promising new treatment approach for rapidly reducing PTSD symptoms is nitrous oxide, an inhalation anesthetic and putative glutamate modulator that diminishes depression symptoms within 1 day and has limited side effects. If shown to be similarly effective in PTSD, nitrous oxide may add dramatically to the treatment armamentarium by bringing rapid symptom decrease before longer-term therapies take hold. The proposed projects test the efficacy of nitrous oxide in relieving Veteran's PTSD symptoms and, in parallel, explore how nitrous oxide may modify cognitive and pain outcomes.

The proposed projects will examine the efficacy of nitrous oxide in relieving Veteran's PTSD symptoms and in parallel, explore whether nitrous oxide improves cognitive and pain outcomes. Specifically, the investigators will first assess whether nitrous oxide treatment improves PTSD symptoms within 1 week. In parallel, the investigators will explore whether the treatment improves co-existing depression and pain. In addition, the investigators will explore nitrous oxide's effects on a PTSD-associated impairment that is often overlooked - disruption in cognitive control, a core neurobiological process critical for regulating thoughts and for successful daily functioning.

Eligibility Criteria:
Inclusion Criteria:

* Veteran
* primary diagnosis of PTSD
* sufficient severity of PTSD symptoms
* capacity to provide informed consent

Exclusion Criteria:

* psychiatric or medical conditions that make participation unsafe
* pregnant or nursing females
* concurrent use of any medications that might increase the risk of participation (e.g. drug interactions
Evaluation of Topical Antipsoriatics in the Psoriasis Plaque Test

The purpose of this study is to evaluate the efficacy of the topical therapies Protopic and Advantan as well as their combination against placebo in a Psoriasis Plaque Test

daily psoriasis plaque tests for two weeks and optical coherence tomography (OCT) and 20-MHz-ultrasound on day 0 and day 11, 10 days post end of treatment and 20 days post end of treatment

Eligibility Criteria:
Inclusion Criteria:

* Patients older than 18 Years
* Negative urine pregnancy test
* Written informed consent
* Good compliance

Exclusion Criteria:

* Patients less than 18 years
* Pregnant patients
* Patients with renal insufficiency, liver diseases
* Patients who received systemic antipsoriatic treatment or UV treatment less than 4 weeks prior to study
* Patients who used topical antipsoriatics within two weeks prior to study
* Immunosuppressed Patients